The group was appointed through Regulation No. 2 of 28 February 2007 (as further amended) of the Council for Counteracting Drug Addiction Chairman.

Team chair:

Marcin Karnaś, Central Bureau of Investigation, Police Headquarters

The tasks of the group are the following:

1. to create a system of comprehensive control over the sale of drug precursors;
2. to improve effectiveness and efficiency of cooperation between the bodies legally appointed to control drug precursors;
3. to initiate changes and extend the list of substances determined in appendices no. 1 and 2 to the Act of 29 July on Counteracting Drug Addiction;
4. to initiate the changes and extend the list of substances determined in appendices to the following regulations: Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors (Official Journal of the European Union L87 of 18.02.2004, p. 1; Official Journal of the European Union, Polish special edition, chapter 15, vol.8, p. 46) and Regulation (EC) No 111/2005 of 22 December 2004 establishing the rules of monitoring the trading of drug precursors between the Community and third countries (Official Journal of the European Union, L22 of 26.01.2005, p.1);
5. to participate in developing drafts of legal acts on monitoring drug precursors;
6. to regularly analyse the legislation on monitoring of drug precursors, including international legislation;
7. to create a system of rapid information exchange between bodies whose representatives are members of the Group, about the manufacturers, wholesalers, importers and exporters of drug precursors with headquarters or offices in Poland.
8. to initiate projects aimed at:
   1. cooperation with the representatives of the chemical and pharmaceutical sectors through the organisation of training sessions and conferences,
   2. building a system of information exchange;
9. cooperation with international organisations and institutions whose competences include monitoring of drug precursors;
10. initiation of strategic and organisational solutions to ensure more effective monitoring of drug precursors;
11. undertaking measures to identify substances used to manufacture the so called legal highs, including new drug precursors